January 12, 2022
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference
Crinetics Pharmaceuticals ($CRNX) will provide a company update at the 40th annual J.P. Morgan Healthcare Conference today, Wednesday, January 12th at 4:30 PM Eastern Time.
January 5, 2022
Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.
Crinetics Pharmaceuticals ($CRNX) announced today that Rogério Vivaldi Coelho, M.D., M.B.A., an expert in rare and orphan diseases, has joined the company's board of directors.
November 18, 2021
Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
Crinetics Pharmaceuticals ($CRNX) announced today that company management will participate in a fireside chat and one-on-one investor meetings at the Annual Evercore ISI HealthCONx Conference.
November 8, 2021
Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress
Crinetics Pharmaceuticals ($CRNX) announced today that new data from ACROBAT Advance, the ongoing open label extension (OLE) trial of paltusotine in patients with acromegaly, will be featured in a poster presentation at the annual Society for Endocrinology BES congress in Edinburgh, Scotland.
November 5, 2021
Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
We also continue to make strong progress in our efforts to develop paltusotine as an oral treatment for acromegaly and neuroendocrine tumors complicated by carcinoid syndrome. With a strong financial foundation that was recently bolstered by our successful common stock offering, we believe we are well positioned to advance our pipeline programs and achieve a regular cadence of milestones.